“A flurry of mergers in the health care sector appears poised to continue, as Bausch & Lomb is said to be ready to sell itself to Valeant Pharmaceuticals of Canada for about $9 billion,” according to a New York Times story. “A deal could be announced as soon as Tuesday, people briefed on the matter said, though they said that talks were continuing and could still collapse. Bausch & Lomb, which makes contact lens solutions and other eye-care products, has been exploring a sale or a public stock offering for a number of months. If completed, a sale may signal that the mergers industry is set to revive after months of fits and starts.” Read more.
No comments:
Post a Comment